Ir directamente a la navegación principal Ir directamente a la búsqueda Ir directamente al contenido principal

A phase II study of addition of pracinostat to a hypomethylating agent in patients with myelodysplastic syndromes who have not responded to previous hypomethylating agent therapy

  • Fevzi F. Yalniz
  • , Jesus G. Berdeja
  • , Michael B. Maris
  • , Roger M. Lyons
  • , James A. Reeves
  • , James H. Essell
  • , Prapti Patel
  • , Mikkael Sekeres
  • , Amanda Hughes
  • , Silvia Mappa
  • , Guillermo Garcia-Manero

Producción científica: Article › revisión exhaustiva

18 Citas (Scopus)

Resumen

Hypomethylating agents (HMAs) are standard of care for higher-risk myelodysplastic syndromes (MDS). However, less than half of patients achieve objective responses and most eventually lose their response. Pracinostat is a pan-histone deacetylase inhibitor with demonstrated activity in advanced myeloid malignancies. This phase II study explored the benefit of adding pracinostat to HMAs in MDS patients who did not respond to single-agent HMA treatment. The goal was to estimate the clinical improvement rate [complete remission (CR), marrow CR, partial response (PR) and haematological improvement]. Group 1 included patients with primary/secondary HMA failures; Group 2 included those who did not achieve response but had stable disease (SD) after single-agent HMAs. Forty-five patients (39 Group 1, 6 Group 2) received a median of 3 cycles. Among all patients, 1 (2%) had CR, 7 (16%) had marrow CR and 18 (40%) had SD; disease progression occurred in 3 (7%). Median overall survival was 5·7/5·6 months for Group 1/2. Grade ≥3 adverse events occurred in 38 patients (84%) leading to treatment discontinuation in 12 (33%). Adding pracinostat to HMAs did not improve outcomes in patients previously treated with HMAs. Frequent dose modifications/early discontinuation resulted in suboptimal drug exposure. A reduced pracinostat dose may improve tolerability and efficacy.

Idioma originalEnglish
Páginas (desde-hasta)404-412
Número de páginas9
PublicaciónBritish Journal of Haematology
Volumen188
N.º3
DOI
EstadoPublished - feb 1 2020

Nota bibliográfica

Publisher Copyright:
© 2019 British Society for Haematology and John Wiley & Sons Ltd

Financiación

The authors would like to thank the patients who participated in this study and the staff at the study sites who cared for them. This study was sponsored and funded by MEI Pharma. Editorial support of formatting the paper for BJH was provided by Jennifer Vanden Burgt, an independent medical writer, and funded by Helsinn Healthcare.

Financiadores
Helsinn Healthcare
Jennifer Vanden Burgt
MEI Pharma

    ASJC Scopus subject areas

    • Hematology

    Huella

    Profundice en los temas de investigación de 'A phase II study of addition of pracinostat to a hypomethylating agent in patients with myelodysplastic syndromes who have not responded to previous hypomethylating agent therapy'. En conjunto forman una huella única.

    Citar esto